Physician profile
Robert C Jones
NPI 1144309121
$56,750.88
in general payments reported to CMS, 2019-2025
26 companies · $11K in 2025
The $11K reported for 2025 was more than what 82% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,986 · 2021: $4,035 · 2022: $12K · 2023: $8,253 · 2024: $7,836 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Travel and Lodging: $2,661 · Food and Beverage: $2,395 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,513.00 |
| Travel and Lodging | $2,660.82 |
| Food and Beverage | $2,394.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $36,979.05 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Selectsecure |
| Medtronic Vascular, INC. | $12,721.40 | 2019-2020 | |
| Medical Device Business Services, INC. | $4,500.00 | 2020-2022 | |
| Pfizer INC. | $957.91 | 2019-2025 | |
| Biosense Webster, INC. | $645.01 | 2019-2025 | Carto 3, Qdot Micro Catheter |
| Abbott Laboratories | $280.07 | 2019-2025 | Tacticath Ablation Catheter, Sensor Enabled, Thoratec Heartmate 3 Lvas Implant Kit, Ensite |
| Merck Sharp & Dohme LLC | $68.69 | 2022-2023 | Verquvo |
| Novo Nordisk INC | $67.19 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $60.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $59.58 | 2023-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $47.41 | 2022 | |
| Altathera Pharmaceuticals LLC | $42.72 | 2023 | Sotalol Hydrochloride |
| Cmp Pharma, INC. | $39.93 | 2022 | |
| Philips North America LLC | $39.33 | 2020-2025 | Ecc Solutions |
| Novartis Pharmaceuticals Corporation | $31.75 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $30.35 | 2024 | |
| Vital Connect, INC | $25.97 | 2023 | Vitalpatch Rtm |
| Atricure, INC. | $22.63 | 2023 | |
| Inspire Medical Systems, INC. | $20.23 | 2024 | Inspire |
| Alnylam Pharmaceuticals INC. | $19.64 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.96 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $18.04 | 2024 | Arcalyst |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.75 | 2025 | Caplyta |
| Kiniksa Pharmaceuticals, LTD. | $14.25 | 2023 | Arcalyst |
| Amgen INC. | $13.03 | 2022 | |
| Medtronic USA, INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.